Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells $4,633,120.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 46,000 shares of BioNTech stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $100.72, for a total transaction of $4,633,120.00. Following the transaction, the chief executive officer owned 410,209 shares of the company’s stock, valued at approximately $41,316,250.48. The trade was a 10.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total transaction of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total transaction of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total value of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total value of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.

BioNTech Price Performance

Shares of BNTX traded up $2.87 during trading hours on Tuesday, reaching $100.87. 1,050,346 shares of the company traded hands, compared to its average volume of 1,100,679. The stock has a market capitalization of $25.51 billion, a PE ratio of -12.88 and a beta of 1.29. The stock has a fifty day simple moving average of $97.54 and a 200 day simple moving average of $94.82. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. During the same quarter last year, the company posted ($1.60) earnings per share. BioNTech’s revenue for the quarter was down 59.5% on a year-over-year basis. As a group, research analysts predict that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several institutional investors and hedge funds have recently bought and sold shares of BNTX. Larson Financial Group LLC raised its stake in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in shares of BioNTech during the 2nd quarter worth $39,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of BioNTech by 1,012.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after buying an additional 506 shares during the last quarter. Vestcor Inc purchased a new position in shares of BioNTech in the 4th quarter worth $153,000. Finally, Rockefeller Capital Management L.P. raised its position in shares of BioNTech by 328.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after buying an additional 1,423 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on BNTX. BMO Capital Markets cut shares of BioNTech from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $128.00 to $105.00 in a research note on Tuesday, September 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. UBS Group restated a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Finally, Canaccord Genuity Group dropped their target price on BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.